52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib
Gatzemeier U, Douillard J, Kris M, Fukuoka M, Herbst R, Schiller J, Wolf M, McPartiane A, Kay A, Fandi A. 52 Rapid and durable objective responses in patients with advanced non-small-cell lung cancer in phase II trials (IDEAL 1 and IDEAL 2) treated with gefitinib. European Journal Of Cancer Supplements 2003, 1: s20. DOI: 10.1016/s1359-6349(03)90087-5.Peer-Reviewed Original ResearchDurable objective responsesPhase II trialCell lung cancerII trialObjective responseLung cancerPatientsGefitinibCancerTrials